H
688302
vs
S
Shanghai Composite
Over the past 12 months, Hinova Pharmaceuticals Inc has significantly outperformed Shanghai Composite, delivering a return of +47% compared to the Shanghai Composite's +25% growth.
Stocks Performance
688302 vs Shanghai Composite
Performance Gap
688302 vs Shanghai Composite
Performance By Year
688302 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hinova Pharmaceuticals Inc
Glance View
Hinova Pharmaceuticals, Inc. engages in the research and development of pharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 160 full-time employees. The company went IPO on 2022-04-12. The firm focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The firm's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The firm has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The firm conducts clinical tests in domestic and overseas areas.
